Influenza A virus subtype H7N9 (H7N9)

Influenza A virus subtype H7N9 is a highly pathogenic avian-origin virus that poses a significant threat to global health due to its pandemic potential and high mortality rate in human infections [1, 5]. The primary molecular targets for both prevention and treatment are the viral surface glycoproteins, Hemagglutinin (H7) and Neuraminidase (N9) [4, 5]. Hemagglutinin facilitates viral entry by binding to sialic acid receptors on host respiratory cells, while Neuraminidase is critical for the release and spread of new viral particles [4]. Monovalent subunit vaccines, which consist of purified H7 and N9 proteins, are designed to elicit protective immune responses by inducing the production of neutralizing antibodies [1, 6]. Because H7-type antigens are notoriously poor at stimulating an immune response in humans, these vaccines are frequently formulated with oil-in-water adjuvants like AS03 or MF59 to enhance efficacy [5, 6]. Beyond vaccination, the virus is targeted by neuraminidase inhibitors such as oseltamivir and zanamivir, which block viral egress, and newer polymerase inhibitors like baloxavir marboxil that halt viral replication [4, 5].

Other names

A/H7N9H7N9 virusAvian influenza A(H7N9)H7N9 subunit antigenInfluenza A/H7N9A/H7N9 Monovalent Subunit Influenza Virus

H7N9 subunit vaccines stimulate the host immune system to produce neutralizing antibodies against the viral Hemagglutinin (H7) and Neuraminidase (N9) proteins, thereby preventing viral entry and spread; neuraminidase inhibitors block the N9 protein to prevent the release of new virions [1, 4, 5].